RD
RDY.US Dr. Reddy’s Laboratories Ltd ADR
- Market cap
- USD 12.4B
- P/E
- 41.4x
- P/B
- 2.98x
- ROE
- 7.1%
- Dividend yield
- 0.57%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.
Is RDY.US undervalued?
Graham numberRDY.US trades 134.1% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Dr. Reddy’s Laboratories Ltd ADR fundamental analysis
No fundamental analysis for Dr. Reddy’s Laboratories Ltd ADR yet.
Dr. Reddy’s Laboratories Ltd ADR stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Dr. Reddy’s Laboratories Ltd ADR
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished do…
Full company profileDr. Reddy’s Laboratories Ltd ADR financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Dr. Reddy’s Laboratories Ltd ADR annual financial statements (INR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 141B | 142B | 154B | 175B | 2.56B | 214B | 246B | 279B | 326B | 353B | 336B |
| Gross Profit | 78.4B | 76.3B | 83.4B | 94.0B | 1.30B | 114B | 139B | 164B | 190B | 187B | 166B |
| Operating Income | 13.5B | 11.9B | 20.9B | 16.0B | 431M | 29.5B | 57.1B | 67.7B | 71.8B | 48.9B | 29.7B |
| EBITDA | 24.8B | 23.6B | 35.5B | 41.8B | 13.2B | 45.1B | 74.4B | 88.4B | 96.7B | 83.3B | 51.0B |
| Net Income | 12.0B | 9.81B | 18.8B | 19.5B | 232M | 23.6B | 45.1B | 55.7B | 56.5B | 45.1B | 27.4B |
| EPS | 14 | 12 | 23 | 23 | 0.28 | 28 | 54 | 67 | 68 | 54 | 33 |
| Balance Sheet | |||||||||||
| Total Assets | 220B | 226B | 225B | 3.07B | 3.63B | 293B | 322B | 388B | 493B | 568B | 577B |
| Total Liabilities | 95.8B | 99.1B | 85.2B | 1.02B | 1.26B | 102B | 90.9B | 107B | 156B | 195B | 186B |
| Shareholders' Equity | 124B | 126B | 140B | 2.05B | 2.37B | 191B | 231B | 281B | 333B | 370B | 388B |
| Cash & Short-term Investments | 18.1B | 21.0B | 24.8B | 340M | 473M | 44.4B | 61.8B | 81.5B | 57.9B | 86.1B | 76.6B |
| Total Debt | 49.2B | 50.7B | 38.4B | 292M | 415M | 33.8B | 13.5B | 20.0B | 46.8B | 75.8B | 72.6B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 21.5B | 18.0B | 28.7B | 29.8B | 35.7B | 28.1B | 58.9B | 45.4B | 46.4B | 56.6B | 7.53B |
| Capital Expenditure | 41.0B | 11.0B | 7.49B | 6.12B | 12.6B | 19.0B | 18.9B | 27.4B | 34.4B | 24.5B | 12.2B |
| Free Cash Flow | -19.5B | 6.99B | 21.2B | 23.7B | 23.1B | 9.06B | 40.0B | 18.0B | 12.0B | 32.1B | -4.65B |
| Ratios | |||||||||||
| ROE | 9.7% | 7.8% | 13.4% | 951.7% | 9.8% | 12.4% | 19.5% | 19.8% | 17.0% | 12.2% | 7.1% |
| ROA | 5.5% | 4.3% | 8.3% | 635.1% | 6.4% | 8.0% | 14.0% | 14.4% | 11.5% | 7.9% | 4.7% |
| Net Profit Margin | 8.5% | 6.9% | 12.2% | 11.2% | 9.1% | 11.0% | 18.3% | 19.9% | 17.4% | 12.8% | 8.2% |
| Debt to Equity | 0.40x | 0.40x | 0.27x | 0.14x | 0.18x | 0.18x | 0.06x | 0.07x | 0.14x | 0.21x | 0.19x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Dr. Reddy’s Laboratories Ltd ADR dividends
- Dividend yield
- 0.57%
- Forward dividend
- 0.08 USD
- Payout ratio
- 15.5%
- Ex-dividend date
- Jul 9, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | INR 7.01B | 8.41 | 15.5% |
| 2025 | INR 6.66B | 7.99 | 11.8% |
| 2024 | INR 6.65B | 7.98 | 11.9% |
| 2023 | INR 4.98B | 5.99 | 11.0% |
| 2022 | INR 4.15B | 4.99 | 17.6% |
| 2021 | INR 4.15B | 4.99 | 1,785.9% |
| 2020 | INR 3.92B | 4.72 | 20.1% |
| 2019 | INR 4.00B | 4.82 | 21.3% |
| 2018 | INR 3.99B | 4.80 | 40.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 5:1 on Nov 5, 2024.
Who owns Dr. Reddy’s Laboratories Ltd ADR
- Insiders 0.00%
- Institutions 16.31%
- Public & others 83.69%
- Shares outstanding 834M
- Free float 3.59B
Top funds holding RDY.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| RBC Emerging Markets Equity Fund F | 4.43M | 0.53% | -2.92% | Sep 2026 |
| AB Emerging Markets Opportunities ETF | 3.54M | 0.42% | +0.12% | Oct 2026 |
| Vanguard Emerging Mkts Stock Idx Inv | 1.87M | 0.22% | 0.00% | Sep 2026 |
| Templeton Emerging Mkts Invmt Tr TEMIT | 1.69M | 0.20% | +13.92% | Sep 2026 |
| Avantis Emerging Markets Equity ETF | 1.67M | 0.20% | 0.00% | Oct 2026 |
| State Street® SPDR® Portfolio EM ETF | 1.44M | 0.17% | 0.00% | Oct 2026 |
| Vanguard Global Minimum Volatility Admr | 1.37M | 0.16% | -10.05% | Sep 2026 |
| DFA Emerging Markets Core Equity 2 I | 1.35M | 0.16% | 0.00% | Sep 2026 |
| Templeton Emerging Markets Equity A | 1.30M | 0.16% | +22.76% | Sep 2026 |
| Templeton Emerging Markets A(Ydis)USD | 1.21M | 0.15% | +26.84% | Sep 2026 |
| Vanguard Total Intl Stock Index Inv | 874K | 0.10% | 0.00% | Sep 2026 |
| RAM (Lux) Sys Emg Mkts Equities B USD | 833K | 0.10% | +43.80% | Sep 2026 |
| JPM Emerging Mkts Opps A acc USD | 710K | 0.09% | -5.67% | Sep 2026 |
| onemarkets J.P. Morgan Em Cntrs E EURAcc | 611K | 0.07% | +3.50% | Aug 2026 |
| Dimensional EM LrgCap Core Eq USD Acc | 551K | 0.07% | -0.30% | Sep 2026 |
| Templeton Emerging Markets A | 515K | 0.06% | +12.99% | Sep 2026 |
| DFA Emerging Markets I | 500K | 0.06% | -0.73% | Sep 2026 |
| SEI Emerging Markets Equity F (SIT) | 484K | 0.06% | +2.18% | Oct 2026 |
| Robeco QI Emerging Cnsrv Eqs I € | 442K | 0.05% | -54.52% | Sep 2026 |
| MI Select ManagersGlblandEmOpportsInsAcc | 386K | 0.05% | +19.46% | Oct 2026 |
Top institutions holding RDY.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Robeco Institutional Asset Management BV | 18.0M | 2.16% | +4.91% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 10.9M | 1.31% | +16.70% | Jun 2026 |
| BlackRock Inc | 10.6M | 1.27% | -8.64% | Jun 2026 |
| Royal Bank of Canada | 9.21M | 1.11% | -7.72% | Jun 2026 |
| Aikya Investment Management Ltd | 9.07M | 1.09% | +6.77% | Sep 2026 |
| Renaissance Technologies Corp | 6.98M | 0.84% | -4.96% | Sep 2026 |
| Dimensional Fund Advisors, Inc. | 5.22M | 0.63% | -1.67% | Sep 2026 |
| State Street Corp | 4.12M | 0.50% | +2.45% | Jun 2026 |
| JPMorgan Chase & Co | 4.07M | 0.49% | -6.91% | Jun 2026 |
| AllianceBernstein L.P. | 3.73M | 0.45% | +46.77% | Jun 2026 |
| Vanguard Capital Management, LLC | 3.10M | 0.37% | 0.00% | Jun 2026 |
| Franklin Templeton Inc | 2.84M | 0.34% | -0.40% | Jun 2026 |
| Nuveen, LLC | 2.83M | 0.34% | 0.00% | Jun 2026 |
| BNP Paribas Arbitrage, SA | 2.65M | 0.32% | -16.77% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 2.03M | 0.24% | -23.98% | Jun 2026 |
| Acadian Asset Management LLC | 1.97M | 0.24% | -12.71% | Sep 2026 |
| American Century Companies Inc | 1.92M | 0.23% | +5.13% | Sep 2026 |
| Bessemer Group Inc | 1.86M | 0.22% | +1.86% | Jun 2026 |
| UBS Group AG | 1.66M | 0.20% | +6.84% | Jun 2026 |
| Schroder Investment Management Group | 1.62M | 0.19% | +792.97% | Jun 2026 |
Dr. Reddy’s Laboratories Ltd ADR company profile
- Company name
- Dr. Reddy’s Laboratories Ltd ADR
- Ticker
- RDY.US
- Exchange
- USA Stocks
- Listed since
- Apr 11, 2001
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 27,527
- Fiscal year end
- March
- Address
- 8-2-337, Road No. 3, Hyderabad, India, 500034
- Phone
- 91 40 4900 2900
- Website
- drreddys.com
About Dr. Reddy’s Laboratories Ltd ADR
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. Its Others segment engages in developing therapies in the fields of oncology and inflammation; and research, development, and commercialization of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines, vitamins and minerals, and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Dr. Reddy’s Laboratories Ltd ADR management
5- Mr. Gunupati Venkateswara Prasad B.E.Co-Chairman, MD & Member of Management Council · born 1960
- Mr. Kallam Satish Reddy B.Tech., M.S.Chairman of the Board & Member of the Management Council · born 1967
- Mr. Erez Israeli M.B.A.CEO & Member of the Management Council · born 1968
- Mr. Mannam VenkatanarasimhamCFO & Member of the Management Council · born 1970
- Mr. Krishna K. Venkatesh B.Pharma M.S.Global Head of IPDO, Integrated Product Development & Member of the Management Council · born 1973